1 Test. 19 Targets.  

Lower respiratory tract infections (LRTIs) represent a significant global health burden associated with substantial morbidity and mortality. Severe pneumonia can lead to life-threatening complications including respiratory failure and sepsis, particularly affecting pediatric, geriatric, and immunocompromised populations.

Our 19-in-1 Lower Respiratory panel utilizes multiplex PCR technology to simultaneously detect 19 clinically relevant bacterial pathogens. Compared to conventional methods, this assay demonstrates superior sensitivity and significantly reduced turnaround time, delivering reliable results within 48 minutes to support evidence-based clinical decision-making.